ジャクソン・ラボラトリー・ジャパンがAvidity Scienceと共に、AIを活用した革新的な実験動物モニタリングシステムを日本で販売開始。研究の効率化と動物福祉に寄与します。

ジャクソン・ラボラトリー・ジャパンとAvidity Scienceが提携し、AIによる行動モニタリングシステムを発表。動物福祉と研究効率を両立します。

CD45.2 (C57BL/6J) and B6.GFP (C57BL/6-Tg(UBC-GFP)30Scha/J) mice were purchased from the Jackson Laboratory (strains 000664 and 004354, respectively); CD45.1 (B6.SJL Ptprca), OT-I.CD45.1 (B6(Ly5.1)-[Tg]TCR OT-I-[KO]RAG1) and OT-I.CD45.2 (C57BL/6NAi-[Tg]TCR OT-I-[KO]RAG1) were obtained from the NIAID-Taconic exchange programme (strains 8478, 300 and 175, respectively)...

Nature, Published online: 26 November 2025; doi:10.1038/s41586-025-09440-x PD-1 blockade interferes with the selective expansion and maintenance of high-affinity TCR stem-like clones that have a critical role in effective checkpoint blockade therapy.

Novartis acquired Avidity Biosciences for $12B after 14 CEO calls and 4 months of talks. CEOs Vas Narasimhan and Sarah Boyce finalized deal at $72/share, up from $52 initial offer.

UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.

Ensign Peak Advisors Inc grew its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 60.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 530,814 shares of the biotechnology compa

Autophagy enables cells to selectively degrade a wide range of macromolecules, and how this process achieves spatial precision within the densely packed cytosol is an active area of investigation. Rec...

Avidity Biosciences has announced a Managed Access Program for del-zota, an innovative therapy for Duchenne Muscular Dystrophy, aimed at supporting patients with specific gene mutations.

Avidity Biosciences (Nasdaq: RNA) announced a U.S. Managed Access Program (MAP) to provide investigational delpacibart zotadirsen (del-zota) to eligible people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) under an FDA-authorized treatment protocol.Enrollment is anticipated to begin by year-end 2025, and participants in EXPLORE44-OLE may transition to the MAP after completing two years of treatment. Avidity aligned with FDA after an October 2025 pre-BLA meeting and plans a BLA submission in 2026 seeking accelerated approval; patients would move to commercial supply if approved. Full MAP eligibility details will be posted on clinicaltrials.gov.